The EpiPen buyers leading price-gouging litigation against two top drugmakers won preliminary approval from a federal judge in Kansas for their $345 million settlement with
Judge Daniel D. Crabtree signed off tentatively on the agreement, which would resolve class action antitrust claims brought against Pfizer in the U.S. District Court for the District of Kansas on behalf of “end payers” like the insurers, pension funds, and consumers that have targeted the two drug giants.
The deal disclosed July 15 is “the result of serious, extensive ...